Delta-tocotrienol Inhibitors Might Reduce Risk of Tumor Invasion and Metastasis


The World Health Organization classifies lung cancer as the most common type of cancer worldwide, both in men and women. The mortality rate is so high that about 1 in 5 deaths are as of result of this terrible disease

News of a possible new way of dealing with lung cancer brought a lot of hope not only in the medical world but also for millions of patients around the globe.

A recent study exploring the possibility of using Delta-tocotrienol, a compound found in vitamin E, has surfaced. As it has shown to have anticancer properties, it is being tested on several types of non-small cell lung cancers (NSCLC), including squamous cell, large cell carcinoma and adenocarcinomas, to try and inhibit signals between tumors cells. By preventing matrix metalloproteinase 9 (MMP-9) migration and invasion of other cells, researchers are trying to prevent cancer development at initial stages, as soon as possible after diagnosis.

Over the past decades, lung cancer has become more and more frequent, and unfortunately, the survival rate past five years has not improved at all, barely reaching 5% out of all cases.

A vaccine that could directly attack tumor cells by attenuating cell invasion and possibly delaying metastasis in NSCLC, would be an important breakthrough.

While the study concludes that “treatment with the tocotrienol mixture resulted in a dosedependent and significant decrease in cell growth, cell migration, tumor invasiveness, and induction of apoptosis”, it is important to remember that these are only preliminary findings and the road to seeing these results put into application is still ahead.